Anticipate Rxs for Inpefa, a New Med for Heart Failure

July 2023

New Rx Inpefa (sotagliflozin) will join Farxiga (dapagliflozin), Jardiance (empagliflozin), and other SGLT2 inhibitors.

But Inpefa is the only SGLT2 inhibitor NOT yet approved for treating type 2 diabetes.

It’s currently only approved to reduce the risk of heart failure urgent care visits, hospitalizations, and cardiovascular (CV) death...in certain adults with OR without diabetes.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Med Safety Avoid Taking Shortcuts With Barcodes
Cardiology Anticipate Rxs for Inpefa, a New Med for Heart Failure
Warts Help Pick Through Products for Warts
New Drugs Think of Atorvaliq as the Liquid Version of Atorvastatin
Dispensing Prevent Confusion When Med Expiration Dates Are Extended
Allergic Reactions Be Specific When Documenting Reactions to Iodine
Practice Help Address Nonmedical Factors Impacting Care
Hypothyroidism Limit Mishaps With Hypothyroid Meds
Opioids Listen for Questions About Opioids INCREASING Pain

Anticipate Rxs for Inpefa, a New Med for Heart Failure

Practical advice for a better career, with unlimited access to CE

Table of Contents